KB2115 which is a compound with promising properties for treatment of obesity and dyslipidemia. KB2115 increases the body’s energy consumption and reduces body weight and markedly reduces blood lipids and blood glucose.
Investigated for use/treatment in hyperlipidemia, metabolic disease, and obesity.
KB2115 is liver selectuve TR agonist that can induce pharmacological effects in the liver. It increases energy consumption, reduces body weight and also markedly reduces blood lipids and blood glucose levels at doses not affecting heart rate, bone density or TSH levels.
Mechanism of action
KB2115 works by selectively stimulating the thyroid hormone
receptor which is the protein in the body that mediates the effects of thyroid hormone. KB2115 has receptor and tissue selective properties and thereby negative effects on the heart can be avoided.
Isoform Alpha-1: Nuclear hormone receptor that can act as a repressor or activator of transcription. High affinity receptor for thyroid hormones, including triiodothyronine and thyroxine.Isoform Alpha-2: Does not bind thyroid hormone and functions as a weak dominant negative inhibitor of thyroid hormone action.